Ernexa Therapeutics Inc. (ERNA) Stock Score, Valuation & Financial Research

Ernexa Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ERNA

Ernexa Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.24. These figures are a research snapshot, not a buy or sell recommendation.

What Ernexa Therapeutics Inc. does

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Ernexa Therapeutics Inc. is a preclinical-stage biotechnology company focused on the development of synthetic allogeneic iMSC therapies for autoimmune diseases. As a preclinical entity, the company does not currently generate revenue from product sales and relies on capital raises and financing activities to fund its research, development, and clinical trial operations.

Products and services

  • The company is developing ERNA-101, a synthetic allogeneic iMSC therapy candidate currently in preclinical development for the treatment of autoimmune diseases.

Business relationships and partnerships

  • Brookline Capital Markets — Engaged as a placement agent for the company's securities offerings. Source

Business strengths to evaluate

  • Experienced management team Source

Business risks and research considerations

  • Preclinical stage of development and lack of operating history Source
  • Requirement for significant additional capital to fund operations Source
  • Regulatory risks associated with FDA approval processes Source

Sources: Company research source · Brookline Capital Markets · Regulatory risks associated with FDA approval processes

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ERNA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.24
Market capitalization:
3.65M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -12.26M
Free cash flow:
USD -7.05M
Cash:
USD 5.03M
Total debt:
USD 349K
EPS:
USD -18.85

What stands out

  • Free cash flow is USD -7.05M, negative for the stored period.
  • The balance sheet shows USD 5.03M of cash versus USD 349K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.68M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ERNA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ERNA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ERNA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ERNA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ERNA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ERNA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.